CNS & Neurological Disorders - Drug Targets
Title:Message from the Editor-in-Chief
Volume: 18 Issue: 1
Author(s): Cesar V. Borlongan
Affiliation:
Export Options
About this article
Cite this article as:
V. Borlongan Cesar , Message from the Editor-in-Chief, CNS & Neurological Disorders - Drug Targets 2019; 18 (1) . https://dx.doi.org/10.2174/187152731801181220123413
DOI https://dx.doi.org/10.2174/187152731801181220123413 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
27
2
1
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring the Selectivity Profile of Sigma Receptor Ligands by Molecular Docking and Pharmacophore Analyses
Medicinal Chemistry Antidepressant Use in Children and Adolescents Diagnosed with Major Depressive Disorder: What Can We Learn from Published Data?
Reviews on Recent Clinical Trials Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets Cellular Internalization of Quantum Dots Mediated by Cell-Penetrating Peptides
Pharmaceutical Nanotechnology Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry Melatonin Effects on Plasmodium Life Cycle: New Avenues for Therapeutic Approach
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Congenital Muscular Dystrophy 1D Causes Matrix Metalloproteinase Activation And Blood-Brain Barrier Impairment
Current Neurovascular Research Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry Therapeutic Chelators for the Twenty First Century: New Treatments for Iron and Copper Mediated Inflammatory and Neurological Disorders
Current Drug Delivery The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies
Current Neuropharmacology Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research β -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?
Current Pharmaceutical Design Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis
Current Pharmaceutical Design Novel Targets for Drugs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinsons Disease
Mini-Reviews in Medicinal Chemistry The Effect of Morphine on the Expression of COX-2 and iNOS Enzymes
Central Nervous System Agents in Medicinal Chemistry C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome
CNS & Neurological Disorders - Drug Targets Psychotherapy, Suicide and Depression, Body Dysmorphic Disorder, Aggression, an Unusual Case, and the Case for Harm Reduction in Treating Adolescent Substance Abuse
Adolescent Psychiatry Cannabidiol as a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development
Current Pharmacogenomics and Personalized Medicine